by CSL shares have had a buoyant start to the week, but despite gaining 2.6 per cent by 2:00pm, are still sitting just below the $270 mark.
The biotech giant is in the final stages of producing the first batches of AstraZeneca vaccines for Australians this week, and parliamentarians will be able to grill the company on its processes tomorrow when CSL takes the hot seat at the Senate Select Committee for COVID-19.
CSL had been invited to present to the committee a few weeks ago along with Pfizer and AstraZeneca representatives, but said at the time it was too busy with vaccine making to dial in for the Canberra hearing.
The company will now appear by itself tomorrow afternoon.
In a submission to the committee ahead of the meeting, CSL warned it might not be much help on sharing contractual details of its arrangement to produce 50 million doses of the AstraZeneca vaccine, however.
CSL is bound by obligations of confidence to both AstraZeneca and Department of Health with respect to the specific terms of its contracts and related activities, which limit CSLs ability to elaborate with any degree of specificity on these contractual arrangements, executive director of CSLs COVID projects lead, Dr Beverley Menner, warned.
